Literature DB >> 12827294

Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents.

Patrizia Vernole1, Rita Pepponi, Stefania D'Atri.   

Abstract

PURPOSE: The mismatch repair (MMR) system plays a major role in mediating the cytotoxicity and clastogenicity of agents generating O(6)-methylguanine in DNA. Loss of MMR has also been associated with tumor cell resistance to the cytotoxic effects of 6-thioguanine and cisplatin and with hypersensitivity to N-(2-chloroethyl)- N'-cyclohexyl- N-nitrosourea (CCNU). The aim of the present investigation was to elucidate the role played by the MMR system in the generation of chromosomal damage in cells exposed to 6-thioguanine, cisplatin or CCNU.
METHODS: The MMR-proficient cell lines TK6 and HCT116/3-6, and their MMR-deficient counterparts MT1 and HCT116, were treated with 6-thioguanine, cisplatin or CCNU, and analyzed for cell growth inhibition and chromosomal damage. As a control, similar experiments were performed with the methylating agent temozolomide.
RESULTS: Cytotoxicity, chromosomal aberrations and sister chromatid exchanges induced by 6-thioguanine and temozolomide were significantly reduced in the MMR-deficient cell lines with respect to their MMR-proficient counterparts. In contrast, although conferring some protection against cytotoxicity, the loss of MMR did not affect cytogenetic damage induced by cisplatin. CCNU produced comparable levels of cytotoxicity, chromosomal aberrations and sister chromatid exchanges in both MMR-proficient and MMR-deficient cell lines.
CONCLUSIONS: The MMR system is involved in the generation of chromosomal damage in cells exposed to 6-thioguanine. The system does not play a relevant role in the generation of chromosomal damage in cells treated with CDDP and does not confer protection against the clastogenic effects of CCNU, at least in the cell lines investigated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827294     DOI: 10.1007/s00280-003-0660-6

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability.

Authors:  Jill E Clodfelter; Michael B Gentry; Karin Drotschmann
Journal:  Nucleic Acids Res       Date:  2005-06-09       Impact factor: 16.971

2.  The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.

Authors:  Wenhuan Huang; Zhe Zhong; Chang Luo; Yuzhong Xiao; Limin Li; Xing Zhang; Liu Yang; Kai Xiao; Yichong Ning; Li Chen; Qing Liu; Xiang Hu; Jian Zhang; Xiaofeng Ding; Shuanglin Xiang
Journal:  Theranostics       Date:  2019-07-28       Impact factor: 11.556

3.  NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug.

Authors:  Simona Caporali; Lauretta Levati; Grazia Graziani; Alessia Muzi; Maria Grazia Atzori; Enzo Bonmassar; Giuseppe Palmieri; Paolo A Ascierto; Stefania D'Atri
Journal:  J Transl Med       Date:  2012-12-21       Impact factor: 5.531

Review 4.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors:  Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal:  Cancers (Basel)       Date:  2018-07-23       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.